Abstract
O ver the last decade, quality of life (QOL) has become an important outcome in clinical trials and in research on the quality of healthcare, according to Dr Regine Sitruk-Ware, Head of Research & Development for Theramex in Monaco. * One reason for this growing interest is that clinical interventions influence parameters such as physical and social functioning, and mental health. Thus, new therapies have the ability not only to cure disease and alleviate symptoms, but also to improve health-related QOL.
This is a preview of subscription content, log in via an institution to check access.
Additional information
* Dr Sitruk-Ware discussed QOL studies and how to overcome problems of inaccuracy, credibility and integration at the PharmEcon Europe ′95 meeting held in Paris, France, in July this year.
Rights and permissions
About this article
Cite this article
Langsdale, T. Demand for quality-of-life studies is increasing. Pharmacoecon. Outcomes News 40, 3–4 (1995). https://doi.org/10.1007/BF03309870
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03309870